These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Sanz E; Romera M; Bellik L; Marco JI; Unzeta M Med Sci Monit; 2004 Dec; 10(12):BR477-84. PubMed ID: 15567979 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]
9. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393 [TBL] [Abstract][Full Text] [Related]
10. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. Mytilineou C; Radcliffe PM; Olanow CW J Neurochem; 1997 Jan; 68(1):434-6. PubMed ID: 8978757 [TBL] [Abstract][Full Text] [Related]
11. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Jenner P Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581 [No Abstract] [Full Text] [Related]
14. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. Pálfi M; Szökó E; Kálmán M Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880 [TBL] [Abstract][Full Text] [Related]
15. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
16. [Effects of selegiline hydrochloride on intracellular Ca2+ contents in cultured neuronal cells]. Itoh T; Takahata K; Morimoto K; Iwamoto N; Ohde H No To Shinkei; 1998 Dec; 50(12):1093-9. PubMed ID: 9989354 [TBL] [Abstract][Full Text] [Related]
17. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Knoll J Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotective and neuronal rescue effects of selegiline: review. Magyar K; Haberle D Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051 [TBL] [Abstract][Full Text] [Related]
19. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Goggi J; Theofilopoulos S; Riaz SS; Jauniaux E; Stern GM; Bradford HF Neuroreport; 2000 Dec; 11(18):3937-41. PubMed ID: 11192605 [TBL] [Abstract][Full Text] [Related]